Equilibre

Biopharmaceuticalseqneuro.com

Equilibre is a private, New York-based biopharmaceutical company founded in 2020 that develops differentiated and novel therapeutic candidates, with an apparent neuroscience focus indicated by its eqneuro.com domain and 11-50 employees.

Company typePrivate
Founded2020
HeadquartersNew York, United States
Headcount1–10
GTM typeB2B
OfferingHardware or Manufacturing

Equilibre firmographics

Firmographics

Name: Equilibre
Website: https://eqneuro.com
Company type: Private
Founded year: 2020
Headcount range: 1–10 employees
Short description: Equilibre is a private, New York-based biopharmaceutical company founded in 2020 that develops differentiated and novel therapeutic candidates, with an apparent neuroscience focus indicated by its eqneuro.com domain and 11-50 employees.
Ownership category
akta.pro rank

Equilibre industry classification

Industry

Product category: Biopharmaceuticals
NAICS: Pharmaceutical Preparation Manufacturing (325412)
SIC: In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro primary industry: Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
akta.pro secondary industry: Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

Biopharmaceutical development
Novel therapeutics
Drug discovery
Neuroscience medicines
Therapeutic candidates

Where Equilibre is headquartered

Location

Headquarters

HQ city: New York
HQ country: United States
HQ region: North America

Markets served

Equilibre business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Personnel, Technology or R&D, Operations

Equilibre product offering

Product offering

Core offering

Equilibre is a biopharmaceuticals corporation developing differentiated and novel therapeutic candidates. The company is focused on creating new medicines, with its web domain (eqneuro.com) indicating a neuroscience orientation to its pipeline of therapeutic candidates.

Differentiator

Problem solved

Functional benefit

Companies that use Equilibre

Customer profile

Ideal customer profiles1 record

Equilibre technology and API

Technology

Technology focussed Yes

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Equilibre competitors and assessment

Company assessment

Direct peers

Sage Therapeutics: Sage is a CNS-focused biopharma developing differentiated therapeutics for depression, epilepsy, and other neurological/psychiatric disorders, directly comparable to Equilibre's stated specialty-pharma CNS posture.
Acadia Pharmaceuticals: Acadia is a CNS specialty pharma with approved and pipeline neurology/psychiatry assets, providing a clear comparable for a small CNS-focused biopharma developing novel therapeutic candidates.
Axsome Therapeutics: Axsome is a CNS-focused biopharma commercializing differentiated neurology/psychiatry therapeutics, closely mirroring Equilibre's positioning as a developer of novel CNS candidates.
Denali Therapeutics: Denali is a neuroscience-focused biopharma developing therapeutics for neurodegenerative and other CNS diseases, comparable to Equilibre's eqneuro.com CNS focus and specialty-pharma development model.
Praxis Precision Medicines: Praxis is a CNS-focused clinical-stage biopharma developing therapies for neurological disorders including epilepsy and movement disorders, directly aligned with Equilibre's CNS/neurology development stance.
Neumora Therapeutics: Neumora is a clinical-stage CNS biopharma developing precision medicines for brain diseases, comparable to Equilibre as a venture-backed, neurology-focused developer of novel CNS therapeutics.
Cerevel Therapeutics: Cerevel is a CNS-focused biopharma developing differentiated therapies across neurology and psychiatry, directly comparable in therapeutic-area focus and specialty-pharma development model.
Karuna Therapeutics: Karuna is a CNS biopharma developing novel neuropsychiatric therapeutics, directly comparable to Equilibre's CNS/neurology specialty-pharma profile (now part of BMS, but a relevant benchmark).
Intra-Cellular Therapies: Intra-Cellular Therapies is a CNS specialty pharma developing treatments for neuropsychiatric and neurological disorders, providing a comparable specialty-CNS developer profile.
Voyager Therapeutics: Voyager is a clinical-stage neuroscience company developing gene therapy and other novel modalities for CNS diseases, comparable to Equilibre as a small-cap CNS-focused developer of differentiated therapeutic candidates.

Market position

Customer concentration

Equilibre financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Equilibre leadership team

Management profile

Number of profiles

Profiles1 record

Equilibre funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Equilibre M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Equilibre

What does Equilibre do?

When was Equilibre founded?

Equilibre was founded in 2020. It employs 1 to 10 people.

Where is Equilibre based?

Equilibre is headquartered in New York, United States, in the North America region.

Who are Equilibre's main competitors?

Direct peers on record are Sage Therapeutics, Acadia Pharmaceuticals, Axsome Therapeutics, Denali Therapeutics, Praxis Precision Medicines, Neumora Therapeutics, Cerevel Therapeutics, Karuna Therapeutics, Intra-Cellular Therapies and Voyager Therapeutics.

Does Equilibre have an API?

No public API is recorded for Equilibre.

What industry is Equilibre in?

Equilibre's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 325412 and its SIC code is 2835.